Results 131 to 140 of about 757 (146)

Real-world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID-19: A retrospective cohort study

Journal of Medical Virology, 2023
Pinhua Pan, Furong Zeng, Li-Ping Jin
exaly  

Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study

Journal of Medical Virology, 2023
Zhao-Hui Tong, Xuefeng Liu
exaly  

Azvudine Reduce the In-Hospital Mortality of Patients with COVID-19 Pneumonia

2023
Kaican Zong, Hui Zhou, Wen Li, E Jiang, Yi Liu, Shiying Li   +5 more
openaire   +1 more source

Azvudine

Reactions Weekly
openaire   +2 more sources

Real‐world effectiveness of Azvudine versus nirmatrelvir‐ritonavir in hospitalized patients with COVID‐19

Journal of Medical Virology, 2023
Guangting Zeng, Linlin Wang, Jianqiang Li, Zanling Zhang   +3 more
openaire   +2 more sources

A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study

Advanced Science, 2020
Chang Junbiao, Zujiang Yu, Wenquan Yu
exaly  

Azvudine/ibrutinib

Reactions Weekly
openaire   +1 more source

Azvudine: a reverse transcriptase inhibitor for AIDS and COVID-19 treatment

Bin Yu, Junbiao Chang
openaire   +1 more source

Azvudine promotes thymocyte differentiation to alleviate immunosuppression and inhibit murine tumorigenesis

Chinese Chemical Letters
Xiao-Yi Chen, Ji-Ye Li, Yu-Wei Ding, Na Guo, Jian-Dong Jiang, Gang Ren   +5 more
openaire   +1 more source

Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study

Journal of Infection
Guanyue Su, Zhigang Ren, Guowu Qian
exaly